
WHAT IS CLAIMED IS:

1. A compound of Formula I:



I

or an *N*-oxide thereof, or a pharmaceutically acceptable salt of said compound or said *N*-oxide, wherein:

X^1 is O or S;

Y^1 is O, S, or NR^N;

Q^1 is an N-containing 5- to 10-membered heterocycloalkyl, an N-containing 5- to 10-membered heteroaryl, or phenyl, wherein the heterocycloalkyl or heteroaryl is optionally substituted with 1, 2, 3, 4, or 5 independently selected R^7; and the phenyl is optionally substituted with 1, 2, 3, 4, or 5 independently selected R^{7a};

R^{T1} and R^{T2} are each independently selected from the group consisting of H, C_{1-3} alkyl, C_{1-3} fluoroalkyl, cyclopropyl, fluorocyclopropyl, C_{1-3} alkoxy, C_{1-3} haloalkoxy, -C(=O)-O-(C_{1-3} alkyl), and -C(=O)OH;

R^1 is selected from the group consisting of H, F, -C(=O)OH, -C(=O)-O-(C_{1-3} alkyl), C_{1-3} alkyl, C_{1-3} fluoroalkyl, C_{3-6} cycloalkyl, and C_{3-6} fluorocycloalkyl, wherein said C_{3-6} cycloalkyl is optionally substituted with 1, 2, 3, 4, or 5 substituents each independently selected from halo, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxy, and C_{1-4} haloalkoxy;

R^2 is selected from the group consisting of H, halogen, -CN, -OH, C(=O)OH, C(=O)-O-(C_{1-3} alkyl), C_{1-3} alkoxy, C_{1-3} haloalkoxy, -N(R^8)(R^9), C_{1-3} alkyl, C_{1-3} fluoroalkyl, C_{3-6} cycloalkyl, C_{3-6} fluorocycloalkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl, wherein said C_{3-6} cycloalkyl is optionally substituted with 1, 2, 3, 4, or 5 substituents each independently selected from halo, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxy, and C_{1-4} haloalkoxy;

R^3 and R^4 are each independently selected from the group consisting of H, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, -CN, C_{3-6} cycloalkyl, -C(=O)OH, C(=O)-O-(C_{1-4} alkyl), and halogen, wherein each of said C_{1-6} alkyl and C_{3-6} cycloalkyl is optionally substituted with 1, 2, 3, 4, or 5 substituents each independently selected from halo, -OH, -CN, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxy, and C_{1-4} haloalkoxy;

R^5 and R^6 are each independently selected from the group consisting of H, halogen, -OH, -NO_2, -CN, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, a 4- to 10-membered heterocycloalkyl, -N(R^8)(R^9), -N(R^{10})(C(=O)R^{11}), -C(=O)-N(R^8)(R^9), -C(=O)-R^{12}, -C(=O)-OR^{12}, and -OR^{13}, wherein each of said C_{1-6} alkyl, C_{3-7} cycloalkyl, and heterocycloalkyl is optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of halogen, -CN, -OH, C_{1-3} alkyl, C_{1-3} alkoxy, C_{1-3} haloalkyl, C_{1-3} haloalkoxy, C_{3-6} cycloalkyl, -N(R^{14})(R^{15}), -N(R^{16})(C(=O)R^{17}), -C(=O)-OR^{18}, -C(=O)H, -C(=O)R^{18}, -C(=O)N(R^{14})(R^{15}), and -OR^{19};

or R^5 and R^3 together with the two carbon atoms to which they are attached form a fused N-containing 5- or 6-membered heteroaryl, a fused N-containing 5- or 6-membered heterocycloalkyl, a fused 5- or 6-membered cycloalkyl, or a fused benzene ring, each optionally substituted with 1, 2, or

3 substituents each independently selected from the group consisting of halo, -CN, -OH, C_{1-3} alkyl, C_{1-3} alkoxy, C_{1-3} haloalkyl, and C_{1-3} haloalkoxy;

R^7 and R^{7a} are each independently selected from the group consisting of halogen, -OH, -CN, $-NO_2$, oxo, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxylalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{3-7} cycloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{6-10} aryl, a 4- to 10-membered heterocycloalkyl, a 5- to 10-membered heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, heteroarylalkenyl, -CH=N-O-(C_{1-3} alkyl), $-N(R^{14})(R^{15})$, $-N(R^{16})(C(=O)R^{17})$, $-S(=O)_2N(R^{14})(R^{15})$, $-C(=O)N(R^{14})(R^{15})$, $-C(=O)-R^{12}$, $-C(=O)-OR^{18}$, and $-OR^{19}$, wherein each of said C_{1-6} alkyl, C_{3-7} cycloalkyl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, heteroarylalkenyl, C_{6-10} aryl, heterocycloalkyl and heteroaryl is optionally substituted with 1, 2, 3, or 4 substituents each independently selected from the group consisting of halogen, OH, -CN, $-NO_2$, C_{1-4} alkyl, C_{1-4} hydroxylalkyl, C_{1-4} alkoxy, $-N(R^{14})(R^{15})$, -S-(C_{1-3} alkyl), $-S(=O)_2$-(C_{1-4} alkyl), aryloxy, arylalkyloxy optionally substituted with 1 or 2 C_{1-4} alkyl, oxo, -C(=O)H, $-C(=O)$-C_{1-4} alkyl, $-C(=O)O$-C_{1-4} alkyl, $-C(=O)NH_2$, -NHC(=O)H, $-NHC(=O)$-(C_{1-4} alkyl), C_{3-7} cycloalkyl, a 5- or 6-membered heteroaryl, C_{1-4} haloalkyl, and C_{1-4} haloalkoxy;

or two adjacent R^{7a} together with the two carbon atoms to which they are attached form a fused 5- or 6-membered cycloalkyl , a fused 5- or 6-membered heterocycloalkyl, or a fused benzene ring, each optionally substituted with 1, 2, 3, or 4 R^{7b}, wherein each R^{7b} is independently selected from the group consisting of halo, -CN, $-NO_2$, $-NH_2$, -NH(C_{1-4} alkyl), $-N(C_{1-4}$ alkyl$)_2$, azetidin-1-yl, pyrrolidin-1-yl, pyridin-1-yl, OH, oxo, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} hydroxylalkyl, C_{1-4} haloalkyl, and C_{1-4} haloalkoxy;

R^8 and R^9 are each independently selected from the group consisting of H, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, a 4- to 10-membered heterocycloalkyl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, and heteroarylalkyl, wherein each of said C_{1-6} alkyl, C_{3-10} cycloalkyl, 4- to 10-membered heterocycloalkyl, cycloalkylalkyl, arylalkyl, and heteroarylalkyl is optionally substituted with 1, 2, 3, or 4 substituents each independently selected from the group consisting of -OH, -CN, C_{1-3} alkyl, C_{3-7} cycloalkyl, C_{1-3} hydroxylalkyl, -S-C_{1-3} alkyl, -C(=O)H, -C(=O)-C_{1-3} alkyl, -C(=O)-O-C_{1-3} alkyl, -C(=O)-NH_2, -C(=O)-N(C_{1-3} alkyl)$_2$, C_{1-3} haloalkyl, C_{1-3} alkoxy, and C_{1-3} haloalkoxy;

or R^8 and R^9 together with the N atom to which they are attached form a 4- to 10-membered heterocycloalkyl or heteroaryl optionally substituted with 1, 2, 3, or 4 substituents each independently selected from the group consisting of halogen, -OH, oxo, -C(=O)H, -C(=O)OH, -C(=O)-C_{1-3} alkyl, -C(=O)-NH_2, -C(=O)-N(C_{1-3} alkyl)$_2$, -CN, C_{1-3} alkyl, C_{1-3} alkoxy, C_{1-3} hydroxylalkyl, C_{1-3} haloalkyl, and C_{1-3} haloalkoxy;

R^{10} is selected from the group consisting of H, C_{1-3} alkyl, and C_{3-7} cycloalkyl;

R^{11} is selected from the group consisting of C_{1-6} alkyl, C_{3-7} cycloalkyl, a 4- to 14-membered heterocycloalkyl, C_{6-10} aryl, a 5- to 10-membered heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, and heteroarylalkyl, each optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of halogen, -CF_3, -CN, -OH, oxo, -S-C_{1-3} alkyl, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, C_{1-6} alkoxy, and C_{1-6} haloalkoxy;

R^{12} is H or is selected from the group consisting of C_{1-10} alkyl, C_{3-7} cycloalkyl, a 4- to 14-membered heterocycloalkyl, C_{6-10} aryl, a 5- to 10-

membered heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, and heteroarylalkyl, each optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of halogen, -CF_3, -CN, -OH, -C(=O)OH, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, C_{1-6} alkoxy, and C_{1-6} haloalkoxy;

R^{13} is selected from the group consisting of C_{1-10} alkyl, C_{1-6} haloalkyl, C_{3-7} cycloalkyl, a 4- to 14-membered heterocycloalkyl, C_{6-10} aryl, a 5- to 10-membered heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, and heteroarylalkyl, each optionally substituted with 1, 2, 3, or 4 substituents each independently selected from the group consisting of halogen, -$N(R^{14})(R^{15})$, -$C(=O)N(R^{14})(R^{15})$, -$N(R^{16})(C(=O)R^{17})$, -C(=O)H, -$C(=O)N(R^{16})(OR^{18})$, -$C(=O)$-R^{18}, -$C(=O)$-OR^{18}, -O-$C(=O)R^{18}$, -CF_3, -CN, -OH, -O-(C_{1-6} hydroxylalkyl), C_{1-6} alkyl, oxo, C_{1-6} hydroxylalkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, C_{1-6} alkoxy, and C_{1-6} haloalkoxy;

R^{14} and R^{15} are each independently selected from the group consisting of H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-10} cycloalkyl, a 4- to 14-membered heterocycloalkyl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, and heteroarylalkyl, wherein each of said C_{1-6} alkyl, C_{3-7} cycloalkyl, cycloalkylalkyl, arylalkyl, and heteroarylalkyl is optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of -OH, -CN, oxo, -NHC(=O)-(C_{1-3} alkyl), -C(=O)N(C_{1-3} alkyl)$_2$, -O-(C_{1-6} hydroxylalkyl), -$S(=O)_2$-C_{1-3} alkyl, -S-C_{1-3} alkyl, C_{1-3} alkyl, C_{3-7} cycloalkyl, C_{1-3} hydroxylalkyl, a 5- to 10-membered heteroaryl, C_{1-3} alkoxy, C_{1-3} haloalkyl, and C_{1-3} haloalkoxy;

or R^{14} and R^{15} together with the N atom to which they are attached form a 4- to 10-membered heterocycloalkyl or 5- to 10-membered heteroaryl optionally substituted with 1, 2, or 3 substituents each

independently selected from the group consisting of halogen, oxo, -OH, C_{1-3} alkyl, C_{1-3} alkoxy, C_{1-3} haloalkyl, C_{1-3} haloalkoxy, C_{1-3} hydroxylalkyl, C_{2-4} alkoxyalkyl, oxo, a 5- to 6-membered heteroaryl, $-NH_2$, $-N(C_{1-3}\text{ alkyl})_2$, $-S(=O)_2-C_{1-3}$ alkyl, $-S-C_{1-3}$ alkyl, -C(=O)H, -C(=O)OH, $-C(=O)NH_2$, and $-C(=O)-C_{1-3}$ alkyl;

R^{16} is selected from the group consisting of H, C_{1-3} alkyl, and C_{3-7} cycloalkyl;

R^{17} is selected from the group consisting of C_{1-6} alkyl, C_{3-7} cycloalkyl, a 4- to 14-membered heterocycloalkyl, C_{6-10} aryl, a 5- to 10-membered heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, and heteroarylalkyl, each optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of halogen, $-CF_3$, -CN, -OH, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, C_{1-6} alkoxy, and C_{1-6} haloalkoxy;

R^{18} is H or is selected from the group consisting of C_{1-6} alkyl, C_{3-7} cycloalkyl, a 4- to 14-membered heterocycloalkyl, C_{6-10} aryl, a 5- to 10-membered heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, and heteroarylalkyl, each optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of halogen, $-CF_3$, -CN, -OH, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, C_{1-6} alkoxy, and C_{1-6} haloalkoxy;

R^{19} is selected from the group consisting of C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-7} cycloalkyl, a 4- to 14-membered heterocycloalkyl, C_{6-10} aryl, a 5- to 10-membered heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, and heteroarylalkyl, each optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of halogen, $-N(R^{14})(R^{15})$, $-C(=O)N(R^{14})(R^{15})$, $-N(R^{16})(C(=O)R^{17})$, $-C(=O)-R^{18}$, $-C(=O)-OR^{18}$, $-CF_3$, -CN,

-OH, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, C_{1-6} alkoxy, and C_{1-6} haloalkoxy; and

R^N is selected from the group consisting of H, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{3-6} fluorocycloalkyl, heteroarylalkyl, and arylalkyl, wherein each of said C_{3-6} cycloalkyl, heteroarylalkyl, and arylalkyl is optionally substituted with 1, 2, 3, 4, or 5 substituents each independently selected from halo, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxy, and C_{1-4} haloalkoxy.


2. The compound of Claim 1, or an *N*-oxide thereof or a pharmaceutically acceptable salt of said compound or said *N*-oxide, wherein Y^1 is O.


3. The compound of Claim 1 or 2, or an *N*-oxide thereof or a pharmaceutically acceptable salt of said compound or said *N*-oxide, wherein X^1 is O.

4. The compound of any one of Claims 1 to 3, or an *N*-oxide thereof or a pharmaceutically acceptable salt of said compound or said *N*-oxide, wherein Q^1 is selected from quinolinyl, isoquinolinyl, 1*H*-imidazo[4,5-*c*]pyridinyl, imidazo[1,2-*a*]pyridinyl, 1*H*-pyrrolo[3,2-*c*]pyridinyl, imidazo[1,2-*a*]pyrazinyl, imidazo[2,1-*c*][1,2,4]triazinyl, imidazo[1,5-*a*]pyrazinyl, imidazo[1,2-*a*]pyrimidinyl, 1*H*-indazolyl, 9*H*-purinyl, pyrimidinyl, pyrazinyl, pyridinyl, pyridazinyl, 1*H*-pyrazolyl, 1*H*-pyrrolyl, 4*H*-pyrazolyl, 4*H*-imidazolyl, imidazo[1,2-*a*]pyrimidinyl, [1,2,4]triazolo[1,5-*a*]pyrimidinyl, [1,2,4]triazolo[4,3-b]pyridazinyl, 1*H*-imidazolyl, 3-oxo-2*H*-pyridazinyl, 1*H*-2-oxo-pyrimidinyl, 1*H*-2-oxo-pyridinyl, 2,4(1*H*,3*H*)-dioxo-pyrimidinyl, and 1*H*-

2-oxo-pyrazinyl, each optionally substituted with 1, 2, 3, or 4 independently selected R^7.

5. The compound of any one of Claims 1 to 3, or an *N*-oxide thereof or a pharmaceutically acceptable salt of said compound or said *N*-oxide, wherein Q^1 is selected from:





each m is independently 0, 1, 2, or 3.

6. The compound of any one of Claims 1 to 5, or an *N*-oxide thereof or a pharmaceutically acceptable salt of said compound or said *N*-oxide, wherein R^{T1} and R^{T2} are both H; R^1 is H; and R^2 is H, -CN, Br, C_{1-3} alkyl, or cyclopropyl.

7. The compound of any one of Claims 1 to 6, or an *N*-oxide thereof or a pharmaceutically acceptable salt of said compound or said *N*-oxide, wherein R^3 and R^4 are each independently selected from the group consisting of H, F, Cl, and C_{1-3} alkyl.

8. The compound of any one of Claims 1 to 7, or an *N*-oxide thereof or a pharmaceutically acceptable salt of said compound or said *N*-oxide, wherein one of R^5 and R^6 is H; and the other of R^5 and R^6 is selected from the group consisting of H, -OH, -CN, Cl, F, methyl, ethyl, CF_3, CH_2F, and -OCH_3.

9. The compound of any one of Claims 1 to 8, or an *N*-oxide thereof or a pharmaceutically acceptable salt of said compound or said *N*-oxide, wherein each of R^7 and R^{7a} is independently selected from the group consisting of C_{1-4} alkyl, C_{1-4} fluoroalkyl, oxo, -OH, C_{1-4} alkoxy, and C_{1-4} haloalkoxy; wherein the C_{1-4} alkyl is optionally substituted with 1, 2, 3, 4, or 5 substituents each independently selected from halogen, OH, C_{1-4} alkoxy, $-NH_2$, $-NH(C_{1-4}$ alkyl), $-N(C_{1-4}$ alkyl$)_2$, azetidin-1-yl, pyrrolidin-1-yl, and pyridin-1-yl.

10. A compound of Claim 1 selected from:

4-[4-(4,6-dimethylpyrimidin-5-yl)-3-methylphenoxy]furo[3,2-*c*]pyridine;

2-(4,6-dimethylpyrimidin-5-yl)-5-(furo[3,2-*c*]pyridin-4-yloxy)benzonitrile;

5-[2-fluoro-4-(furo[3,2-*c*]pyridin-4-yloxy)phenyl]-4,6-dimethylpyridazin-3(2*H*)-one;

5-[4-(furo[3,2-*c*]pyridin-4-yloxy)phenyl]-4,6-dimethylpyridazin-3(2*H*)-one;

(+)-5-[4-(furo[3,2-*c*]pyridin-4-yloxy)-2-methylphenyl]-4,6-dimethylpyridazin-3(2*H*)-one;

(-)-5-[4-(furo[3,2-*c*]pyridin-4-yloxy)-2-methylphenyl]-4,6-dimethylpyridazin-3(2*H*)-one;

5-[4-(furo[3,2-*c*]pyridin-4-yloxy)-2-methylphenyl]-4,6-dimethylpyridazin-3(2*H*)-one;

(+)-5-[4-(furo[3,2-*c*]pyridin-4-yloxy)-2-methylphenyl]-6-methylimidazo[1,2-*a*]pyrazine;

(-)-5-[4-(furo[3,2-*c*]pyridin-4-yloxy)-2-methylphenyl]-6-methylimidazo[1,2-*a*]pyrazine;

5-[4-(furo[3,2-*c*]pyridin-4-yloxy)-2-methylphenyl]-6-methylimidazo[1,2-*a*]pyrazine;

4-[4-(4,6-dimethylpyrimidin-5-yl)-3-fluorophenoxy]furo[3,2-*c*]pyridine;

4-[4-(4,6-dimethylpyrimidin-5-yl)phenoxy]furo[3,2-*c*]pyridine;

(-)-6-[4-(furo[3,2-*c*]pyridin-4-yloxy)-2-methylphenyl]-1,5-dimethylpyrazin-2(1*H*)-one;

(+)-6-[4-(furo[3,2-*c*]pyridin-4-yloxy)-2-methylphenyl]-1,5-dimethylpyrazin-2(1*H*)-one;

6-[4-(furo[3,2-*c*]pyridin-4-yloxy)-2-methylphenyl]-1,5-dimethylpyrazin-2(1*H*)-one;

6-[4-(furo[3,2-*c*]pyridin-4-yloxy)-2-methylphenyl]-1,5-dimethylpyrimidin-2(1*H*)-one;

4-[4-(4,6-dimethylpyrimidin-5-yl)-2-fluorophenoxy]furo[3,2-*c*]pyridine;

5-[4-(furo[3,2-*c*]pyridin-4-yloxy)-2-methylphenyl]-2,4,6-trimethylpyridazin-3(2*H*)-one;

5-[4-(furo[3,2-*c*]pyridin-4-yloxy)-2-methylphenyl]-4-methylpyridazin-3(2*H*)-one;

(+)-4-[4-(3,5-dimethylpyridazin-4-yl)-3-methylphenoxy]furo[3,2-*c*]pyridine;

(-)-4-[4-(3,5-dimethylpyridazin-4-yl)-3-methylphenoxy]furo[3,2-*c*]pyridine;

4-[4-(3,5-dimethylpyridazin-4-yl)-3-methylphenoxy]furo[3,2-*c*]pyridine;

4-[4-(3,5-dimethyl-6-oxo-1,6-dihydropyridazin-4-yl)phenoxy]furo[3,2-*c*]pyridine-3-carbonitrile;

(-)-4-[4-(3,5-dimethylpyridazin-4-yl)-3-methoxyphenoxy]furo[3,2-*c*]pyridine;

(+)-4-[4-(3,5-dimethylpyridazin-4-yl)-3-methoxyphenoxy]furo[3,2-*c*]pyridine;

4-[4-(3,5-dimethylpyridazin-4-yl)-3-methoxyphenoxy]furo[3,2-*c*]pyridine;

6-[4-(furo[3,2-*c*]pyridin-4-yloxy)-2-methylphenyl]-1,5-dimethylpyrimidine-2,4(1*H*,3*H*)-dione;

(-)-6-[4-(furo[3,2-*c*]pyridin-4-yloxy)-2-methylphenyl]-1,5-dimethylpyrimidine-2,4(1*H*,3*H*)-dione;

(+)-6-[4-(furo[3,2-*c*]pyridin-4-yloxy)-2-methylphenyl]-1,5-dimethylpyrimidine-2,4(1*H*,3*H*)-dione; and

6-[4-(furo[3,2-*c*]pyridin-4-yloxy)phenyl]-1,5-dimethylpyrimidine-2,4(1*H*,3*H*)-dione,

or an *N*-oxide thereof or a pharmaceutically acceptable salt of said compound or said *N*-oxide.

11. A pharmaceutical composition comprising a compound according to any one of Claims 1 to10 or an *N*-oxide thereof or a pharmaceutically acceptable salt of said compound or said *N*-oxide, and a pharmaceutically acceptable carrier.

12. A pharmaceutical composition comprising a compound according to any one of Claims 1-10 or an *N*-oxide thereof or a pharmaceutically acceptable salt of said compound or said *N*-oxide for treating a disorder in a mammal, wherein the disorder is selected from schizophrenia, cognitive impairment, attention deficit hyperactivity disorder (ADHD), impulsivity, compulsive gambling, overeating, autism spectrum disorder, mild cognitive impairment (MCI), age-related cognitive decline, dementia, restless leg

syndrome (RLS), Parkinson's disease, Huntington's chorea, anxiety, depression, major depressive disorder (MDD), treatment-resistant depression (TRD), bipolar disorder, chronic apathy, anhedonia, chronic fatigue, post-traumatic stress disorder, seasonal affective disorder, social anxiety disorder, post-partum depression, serotonin syndrome, substance abuse and drug dependence, drug abuse relapse, Tourette's syndrome, tardive dyskinesia, drowsiness, excessive daytime sleepiness, cachexia, inattention, a movement disorder, a therapy-induced movement disorder, sexual dysfunction, migraine, systemic lupus erythematosus (SLE), hyperglycemia, atherosclerosis, dislipidemia, obesity, diabetes, sepsis, post-ischemic tubular necrosis, renal failure, hyponatremia, resistant edema, narcolepsy, hypertension, congestive heart failure, postoperative ocular hypotonia, sleep disorders, and pain.

13. The pharmaceutical composition Claim 12 , wherein said treating schizophrenia is treating a cognitive or negative symptom in schizophrenia; said cognitive impairment is cognitive impairment associated with schizophrenia, cognitive impairment associated with AD, cognitive impairment associated with PD, or cognitive impairment associated with pharmacotherapy therapy; said dementia is senile dementia, HIV-associated dementia, Alzheimer's dementia, Lewy body dementia, vascular dementia, or frontotemporal dementia; said depression is t age-related depression; said movement disorder is dyskinesia, a Tic disorder, or tremor; said therapy-induced movement disorder is a therapy-related dyskinesia or therapy-related tremor; said sexual dysfunction is erectile dysfunction or post-SSRI sexual dysfunction.